Pharmaceutical majors are making unprecedented capital expenditures in fill-finish and active pharmaceutical ingredient production capacity to alleviate chronic shortages of GLP-1 receptor agonist medications.
Contract Manufacturing Expansion
To meet market demand projected to exceed $100 billion by 2030, primary drug originators are acquiring contract development and manufacturing organization sites. Industry filings indicate over $12 billion in dedicated capital commitments for automated peptide synthesis and sterile injector pen assembly lines over the next 24 months.
Payer Coverage Dynamics
Concurrently, insurance providers are tightening prior authorization requirements to manage pharmacy benefit expenditures. Employers and health plans are increasingly demanding real-world evidence of long-term cardiovascular outcomes before agreeing to broad formulary inclusion.